102 results about "Hematological malignancy" patented technology

The invention provides a hematologic tumor cord blood transplantation treatment prognosis index evaluation decision generation method and system based on prediction modeling, a medium and electronic equipment, and relates to the technical field of medical artificial intelligence. The method comprises the following steps: acquiring multi-source data of a key time point in a whole process of blood tumor umbilical cord blood transplantation treatment of a patient; integrating expert knowledge to form an expert knowledge network, taking the expert knowledge network as priori knowledge of multi-target prediction, and performing multi-dimensional prognosis prediction by using multi-source data; periodically acquiring time sequence multi-source data, capturing time evolution characteristics of patient states, and automatically triggering an updating mechanism at a key clinical time point to dynamically adjust a prediction result; generating a risk assessment grade, a feature importance analysis result and an individualized interpretation report based on the prediction result, and performing visualization; and generating a clinical decision using the large language model. According to the technology, accurate evaluation and individualized clinical decision support for hematologic tumor cord blood transplantation prognosis are achieved.

Provided are methods for clinical treatment of hematological malignancies, such as relapsed or refractory chronic lymphocytic leukemia or lymphoma using an anti-LAG-3 antibody. Particular malignancies include, e.g., chronic lymphocytic leukemia (CLL), Hodgkin lymphoma (HL), or non-Hodgkin lymphoma (NHL).

The invention discloses a hematologic tumor calming treatment and protection intervention method based on potential profile analysis, and relates to the technical field of medical treatment and health information analysis, and the method comprises the following steps: S1, constructing a multi-dimensional intervention feature data set; s2, constructing a profile analysis model according to the feature data set; s3, performing category stability verification according to a section analysis result; s4, screening an intervention reference template according to a stability verification result; s5, matching individual features according to the intervention reference template to form a preset intervention path; s6, constructing a profile-driven path execution and feedback control system by using an intervention preset path; by setting a profile response function modeling model and combining a multi-intervention feature matrix to construct a high-resolution profile function, the problem that an existing profile division model is insufficient in continuous variable processing capacity is effectively solved, the profile structure expression capacity and individual heterogeneity description precision are improved, and the profile division efficiency is improved. The method is suitable for the fine layered modeling requirement under the driving of multi-dimensional intervention features.

Disclosed herein are antibodies and compositions used for binding to Gal3. Some embodiments allow for disrupting interactions between Galectin-3 (Gal3) and cell surface markers and / or proteins associated with neurological diseases and / or proteopathies, such as Alzheimer's disease. Additionally, disclosed herein are methods of treatment and uses of the antibodies or binding fragments thereof for the treatment of fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, pulmonary fibrosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, sepsis, atopic dermatitis, psoriasis, cancer, brain cancer, breast cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, bladder cancer, stomach cancer, hematological malignancy, neurological diseases and / or proteopathies. Furthermore, some embodiments provided herein can cross the blood-brain barrier and can be conjugated or otherwise associated with one or more payloads for the treatment of a neurological disease.

The invention discloses an antibody combination, a kit and a method for detecting each development subgroup of bone marrow myeloid cells by flow cytometry. And the antibodies comprise an anti-CD45 antibody, an anti-HLA-DR antibody, an anti-CD13 antibody, an anti-CD11b antibody, an anti-CD34 antibody, an anti-CD64 antibody, an anti-CD45RA antibody, an anti-CD123 antibody, an antiLin antibody and an anti-CD38 antibody. According to the invention, the myeloid cells in the bone marrow microenvironment before and after hematologic tumor treatment can be comprehensively, specifically and conveniently dynamically monitored.

The invention discloses a CD7 and FAS double-gene knockout CD7 CAR-T cell and a preparation method and application thereof.By means of the method, the self-killing phenomenon of the CAR-T cell can be avoided, the cell amplification efficiency and the treatment effect can be improved, in addition, the survival ability and durability of the CAR-T cell can be remarkably enhanced, the method has remarkable advantages in treatment of T cell hematological malignancies, and the method is suitable for being used for treating T cell hematological malignancies. The method has a good application prospect and important conversion significance.

Methods and systems for detecting cancer and / or determining a cancer tissue of origin are disclosed. In some embodiments, a multiclass cancer classifier is disclosed that is trained with a plurality of biological samples containing cfDNA fragments. The analytics system derives a feature vector for each sample, and the multiclass classifier predicts a probability likelihood for each of a plurality of tissue of origin (TOO) classes. In some embodiments, the plurality of TOO classes include hematological subtypes, including both hematological malignancies and precursor conditions. In one embodiment, non-cancer samples having high tissue signal are pruned from the training sample set. In another embodiment, the analytics system stratifies samples according to tissue signal and applies binary threshold cutoffs determined for each stratum.

Described are methods of manufacturing engineered T cells and methods of using the engineered T cells to treat hematological malignancies. The engineered T cells can be administered in combination with allogeneic stem cell transplant and reduce the need for prophylactic immunosuppression.

Described herein are LAG3 specific single domain antibodies and binding molecules comprising such single domain antibodies, as well as nucleic acids encoding the same. Also provided are nucleic acids (e.g., mRNA) encoding such single domain antibodies and binding molecules and delivery vehicles (e.g., lipid nanoparticles) formulated with said nucleic acids. The disclosure also features methods of using such antibodies, binding molecules, nucleic acids, and delivery vehicles formulated with said nucleic acids to treat various diseases such as inflammatory diseases, T cell driven autoimmune diseases, and cancer (e.g., solid tumors or hematological malignancies).

The invention discloses a hematologic tumor diagnosis and treatment primer group, a kit and application. The primer group comprises a first primer group and / or a second primer group, the first primer group is used for amplifying IGH, IGDH, IGK and IGL; the first primer group is used for amplifying TRB V-J, TRB D-J, TRG and TRD, the second primer group is used for amplifying TRB V-J, TRB D-J, TRG and TRD, after the primer groups amplify and rearrange sequences, the positive detection of clinical samples can be remarkably improved, the obtained CDR3 sequence can be used for clinical monitoring and can independently evaluate an immune group library of each patient, the immune state of an individual can be accurately reflected, the change condition of tumor cells of the patient can be dynamically monitored, and the clinical detection efficiency can be improved. And the method has good reliability and repeatability.

The present invention relates to methods for treating patients with cancer, including patients with hematological malignancy, wherein the method comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined herein.

This invention discloses a class of 2-(2-(quinolin-4-yloxy)ethyl)pyridazine-3(2H)-one compounds, their preparation methods, and applications. The structure of these compounds is shown in general formula (I). This invention also discloses that the above compounds have a significant inhibitory effect on interleukin-1 receptor-associated kinase 1 (IRAK1). These compounds can inhibit the proliferation of various tumor cells, including liver cancer, lung cancer, pancreatic cancer, gastric cancer, kidney cancer, colon cancer, esophageal cancer, glioblastoma, leukemia, multiple myeloma, and other solid tumors and hematological malignancies. This invention provides a new option for tumor treatment.

This invention relates to the field of biotechnology, specifically to a TruC-T cell that secretes and expresses IL-7 and PF4 to enhance anti-tumor activity and targets uPAR, and its application. Interleukin-7 (IL-7) can effectively promote the development, survival, and proliferation of T cells, while platelet factor 4 (PF4 / CXCL4) can regulate the immune response and chemotactically attract leukocytes to specific sites; the synergistic effect of the two can enhance the anti-tumor function and persistence of T cells. Meanwhile, urokinase-type plasminogen activator receptor (uPAR) is highly expressed in various solid tumors and hematological malignancies, making it an ideal target for tumor therapy; TruC-T cells targeting uPAR can precisely act on tumor tissue, and combined with the immune-enhancing effects of IL-7 and PF4, can significantly improve the efficacy of anti-tumor immune responses, prolong the duration of therapeutic effects, and reduce tumor recurrence.

The present invention relates to treating malignancies such as tumors or cancers by orally administering lyophilized compositions comprising arsenic to a subject in such need. Malignancies include various hematological malignancies, such as acute myeloid leukemia (AML) including acute promyelocytic leukemia (APL), myelodysplastic syndrome (MDS), multiple myeloma (MM) and lymphomas and solid tumors including glioblastoma multiforme and breast cancer. This invention relates to a novel formulation comprising a lyophilized compositions comprising arsenic. The present invention also relates to a method for lyophilizing the arsenic trioxide, preparing the oral formulation comprising lyophilized compositions comprising arsenic, and a method for treating a subject with malignancies using the oral formulation.

Described herein are methods of treating a hematological malignancy, including minimal residual disease in hematological malignancies, and methods of preventing relapse of hematological malignancies, the methods comprising administering an inflammasome modulator. In some embodiments the method of treatment comprises administering a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein the variables are as defined herein.

The present disclosure relates to antibodies and antibody fragments specific for CCR2. As reactivity with marmoset CCR2, which is a species that is crucial to further preclinical and clinical development, is lost, almost all attempts to humanize the original antibody are notified as failure. The antibodies are useful in the treatment of inflammatory diseases, autoimmune diseases, hematological malignancies, and potentially other diseases.

CD38 is also expressed in a variety of hematological malignancies, including multiple myeloma. In the present invention, the inventors obtained a new antibody against CD38 that can be used to produce bispecific antibodies and CAR T cell populations. In particular, the inventors reported the development of Bi38-3, a new bispecific T cell engager that targets CD38 on MM cells and forms cytotoxic T cells through CD3ε. Bi38-3 lacks the Fc region of natural mAbs, which contributes to the resistance process, but triggers T cell proliferation, cytokine release, and lysis of CD38-positive MM cells in vitro. Similarly, Bi38-3 induces autologous T cells to eliminate tumor plasma cells isolated from MM patients at diagnosis and relapse. The cytotoxicity triggered by Bi38-3 is limited to cells expressing high levels of CD38 and maintains the integrity of T, B, and NK lymphocytes in vitro. Importantly, Bi38-3 rapidly reduced tumor cells in the MM1.S xenograft mouse model of human MM. In summary, the results show that the antibody of the present invention is an effective agent for specifically eliminating CD38-positive malignant cells without significantly affecting CD38-low-expressing cells, and is a promising new immunotherapy tool for treating malignant blood diseases, especially multiple myeloma.

The present disclosure discloses methods and systems for detecting cancer and / or determining tissue of origin of cancer. In some embodiments, a multi-classification cancer classifier is disclosed that is trained using a plurality of biological samples containing cfDNA fragments. The analysis system derives a feature vector for each sample, and the multi-classification classifier predicts a probabilistic likelihood for each of a plurality of cancer signal origin (CSO) classifications. In some embodiments, the plurality of CSO classifications include hematological subtypes, including both hematological malignancies and precursor conditions. In one embodiment, non-cancer samples with high predictive scores are rejected from a training sample set. In another embodiment, the analysis system stratifies the sample according to a predicted score and applies a binary threshold cutoff value determined for each stratification.

The invention discloses a fused ring compound as well as a preparation method and application thereof. The fused ring compound has an excellent treatment effect on solid tumors such as gastric cancer, breast cancer, lung cancer or urothelial cancer or malignant tumors of a blood system.

The present invention relates to methods for treating patients with cancer, including patients with hematological malignancy, wherein the method comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined herein.

Provided herein are formulations, processes, solid forms and methods of use (e.g., methods of treating a hematological malignancy) relating to salts of and solid forms comprising free base or salts of (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione.

To provide anti-Gal3 antibodies and methods of use.SOLUTION: Disclosed herein are antibodies and compositions used for binding to Gal3. Some embodiments allow for disrupting interactions between Gal3 and cell surface markers and / or proteins associated with neurological diseases and / or proteopathies, such as Alzheimer's disease. Additionally, disclosed herein are methods of treatment and uses of antibodies or binding fragments thereof for treatment of fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, pulmonary fibrosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, sepsis, atopic dermatitis, psoriasis, cancer, brain cancer, breast cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, bladder cancer, stomach cancer, hematological malignancy, neurological diseases and / or proteopathies. Furthermore, some embodiments provided herein can cross the blood-brain barrier and can be conjugated or otherwise associated with one or more payloads for the treatment of a neurological disease.SELECTED DRAWING: Figure 1

The present invention relates to methods of treatment of light chain amyloidosis and other CD38-positive hematological malignancies with anti-CD38 antibodies.

This invention belongs to the fields of medicinal chemistry and pharmaceutical technology, and relates to 1,4-benzodiazepines and their use in the preparation of antitumor drugs, specifically the use of 1,4-benzodiazepines in the preparation of annexin A3 (ANXA3) degrading agents and in the preparation of drugs for treating cancer. In particular, it discloses the use of 1,4-benzodiazepines, or pharmaceutically acceptable salts thereof, or stereoisomers thereof, or compositions of drugs with these as active ingredients, in the preparation of drugs for the prevention and treatment of tumors. These compounds can bind to the ANXA3 protein, induce ANXA3 protein degradation, inhibit the proliferation, cloning, migration, and invasion of tumor cells, and exert antitumor therapeutic effects in vivo. They can be used to treat solid tumors and hematological malignancies, including breast cancer, cervical cancer, ovarian cancer, colorectal cancer, gastric cancer, pancreatic cancer, lung cancer, esophageal cancer, liver cancer, leukemia, and melanoma.

The present invention relates to a combination product comprising a Bcl-2 / Bcl-xL inhibitor and a chemotherapeutic agent, in particular a Bcl-2 / Bcl-xL inhibitor of formula I-A and homoharringtonine or an active derivative thereof, in free or pharmaceutically acceptable salt or solvate form. The invention also relates to the use of the aforementioned combination for the preparation of a medicament for the prevention and / or treatment of cancer, in particular of hematological malignancies, and to a method for the prevention and / or treatment of cancer, in particular of hematological malignancies, using the aforementioned combination.

The present disclosure provides methods for treating hematological malignancies and Ewing's sarcoma using menin inhibitors. Compositions for use in these methods are also provided.

To provide formulations of anti-CD38 antibodies suitable for subcutaneous administration to a subject in need thereof.SOLUTION: Formulations include a high concentration of antibody, a viscosity lowering agent, a stabilizing agent, a buffering agent, and a surfactant. In certain embodiments, the viscosity of the solution is at most 25 mPa s, and the pH of the solution is 5.9-7.0. In certain embodiments, the anti-CD38 antibody is isatuximab. The formulations are useful in treating CD38+ hematological malignancies, including multiple myeloma, as well as autoimmune and inflammatory diseases, in humans.SELECTED DRAWING: None

This application relates to an anti-ROR1 antibody, an antibody-drug conjugate containing the antibody, a pharmaceutical composition and medical product containing the antibody-drug conjugate, and a method for producing and using the antibody-drug conjugate, wherein the antibody-drug conjugate is effective in treating and / or preventing ROR1-positive tumors, including hematological malignancies and solid tumors (e.g., cancers such as breast cancer and bladder cancer).

Methods of expanding peripheral blood lymphocytes (PBLs) from blood of patients with hematological malignancies, including lymphomas and leukemias, genetic modifications of expanded PBLs to incorporate chimeric antigen receptors, genetically modified T cell receptors, and other genetic modifications, and uses of such expanded and / or modified PBLs in the treatment of diseases such as cancers and hematological malignancies are disclosed herein.